-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s MK-4830
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s V-184
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s Miransertib Mesylate
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s V-160
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s ODM-208
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Merck & Co Inc's ODM-208 Drug Details: ODM-208 is under development for the treatment of castration resistant prostate cancer. The drug candidate is administered...
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s mRNA-4157
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s Zilovertamab vedotin
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s MK-5475
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s MK-1942
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s MK-0616
OverviewDetermining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models. Merck & Co Inc's MK-0616 Drug Details: MK-0616 is under development for the treatment of atherosclerotic cardiovascular disease (ASCVD) and hypercholesterolemia. It is administered...
-
Product Insights
New![]()
Net Present Value Model: Merck & Co Inc’s MK-2060
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Company Insights
![]()
Merck & Co., Inc. – Digital Transformation Strategies
Merck Digital Transformation Strategies Report Overview Merck & Co., Inc. (Merck) has been focusing on using artificial intelligence, cloud, big data, and 3D printing to digitally transform its operations. The annual ICT spending of Merck was estimated at $3 billion for 2022. A major share of this spending is earmarked for acquiring software, ICT services, and consulting from vendors. Merck is a multinational healthcare company that is engaged in the discovery, development, manufacture, and commercialization of prescription medicines, biological therapies,...
-
Sector Analysis
![]()
Chronic Lymphocytic Leukemia (CLL) Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Chronic Lymphocytic Leukemia (CLL) Market Report Overview The Chronic Lymphocytic Leukemia (CLL) market size for the seven major pharmaceutical markets (7MM) (US, France, Germany, Italy, Spain, UK, and Japan) was at $8.4 billion in 2022. The CLL market will register a CAGR of less than 1% from 2022 to 2032. The CLL market research report offers an overview of CLL, including epidemiology, symptoms, diagnosis, and disease management. The report offers key topics covered including strategic competitor assessment, market characterization, unmet...
-
Product Insights
New![]()
Sleep Apnea Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Sleep Apnea Clinical Trials Overview The Sleep Apnea clinical trial report consists of 613 trials. The report provides an overview of the Sleep Apnea clinical trial scenario. The report provides top-line data relating to the clinical trials on Sleep Apnea. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and...
-
Product Insights
New![]()
Net Present Value Model: BioNTech SE’s BNT-211
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Ewing Sarcoma Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Ewing Sarcoma Clinical Trials Overview The Ewing Sarcoma clinical trial report consists of 430 trials. The report provides an overview of the Ewing Sarcoma clinical trials scenario. The report provides top-line data relating to the clinical trials on Ewing Sarcoma. It also includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and...
-
Product Insights
![]()
Merck & Co – Elkton Manufacturing Plant Expansion – Virginia
Equip yourself with the essential tools needed to make informed and profitable decisions with our Merck & Co - Elkton Manufacturing Plant Expansion - Virginia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
![]()
Merck & Co – Durham Plant Expansion – North Carolina
Equip yourself with the essential tools needed to make informed and profitable decisions with our Merck & Co - Durham Plant Expansion - North Carolina report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
![]()
Merck KGaA – Chandler Chemical Manufacturing Plant – Arizona
Equip yourself with the essential tools needed to make informed and profitable decisions with our Merck KGaA - Chandler Chemical Manufacturing Plant - Arizona report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
![]()
Merck & Co – Wilson Plant Expansion – North Carolina
Equip yourself with the essential tools needed to make informed and profitable decisions with our Merck & Co - Wilson Plant Expansion - North Carolina report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.